Earnings per share for the last twelve months: Apollomics Inc. (APLM)
Apollomics, Inc. (APLM) maintains a high authority in the treatment of aggressive tumors, which minimizes risks, as evidenced by the rolling 12-month earnings per share trend, where the value -0.26 represents the latest figure. However, geopolitical pressure between the US and China could restrict access to capital. Stability will be ensured by patient retention within targeted therapy under the strict oversight of the FDA and NMPA regulators.
Comprehensive metric breakdowns and analytics for Apollomics Inc. (APLM)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- net income and valuation multiples indicators:
APLM - Company Net Income|Expected Profit Apollomics, Inc.|APLM - Price to Earnings Ratio|Forward P/E Multiple Apollomics Corp|APLM - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Apollomics, Inc.|APLM - Operating profit before deduction of amortization|Earnings per share for the last twelve months Apollomics|APLM - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months apollomicsinc.com|APLM - Earnings per share increase in current year|Earnings growth forecast for next year Apollomics, Inc.
Basic company analysis:APLM - apollomicsinc.com
Net income per share over twelve months reflects the actual equity return of the business. This metric is calculated as the ratio of total net income to the number of shares, which neutralizes the impact of one-off transactions. By analyzing the annual EPS TTM snapshot, an investor can identify trend inertia and drawdown risks. For Apollomics, Inc. (APLM), the dynamics of this metric are driven by clinical phase costs. Strict FDA oversight and patent protection make this indicator a key measure of the efficiency of intellectual property capitalization.
Competitor analysis for Apollomics, Inc.
ONC: Net earnings per share for the last 12 months|HALO - Net earnings per share (EPS TTM)|Revolution Medicines, Inc. (RVMD) - Earnings per share for the last twelve months|Ascentage Pharma Group International - Earnings per share for the trailing year|CGON (CG Oncology Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months UroGen Pharma Corp URGN|Net earnings per share (EPS TTM) BCAX|Net earnings per share (EPS TTM) personalis.com (PSNL)|Earnings per share for the last twelve months Erasca ERAS|DCTH (Delcath Systems Inc) - Earnings per one share for the last 12 months|YMAB - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Aura Corp|candeltx.com (CADL) - Earnings per share for the last twelve months|ARAY (accuray.com) - Earnings per share for the last twelve months|Earnings per share for the last twelve months SELLAS Life Sciences Group, Inc.|Earnings per share for the last twelve months ACTU|Earnings per share for the last twelve months Citius Oncology, Inc (CTOR)|HURA - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Protara Therapeutics TARA|FATE - Net earnings per share for the last 12 months|Aadi Bio - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters TScan Therapeutics TCRX|CSBR: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months XBiotech|Earnings per share for the last twelve months CEL-SCI Corp.|ostherapies.com (OSTX) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RADX (Radiopharm Theranostics Limited)|ARTV (artivabio.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ANL (Adlai Nortye)|Net earnings per share for the last four quarters Veru Corporation (VERU)|TPST - Earnings per share for the last twelve months|XLO (Xilio Therapeutics, Inc.) - Earnings per share for the last 12 months|RENB: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Mural Oncology|Net earnings per share for the last 12 months KAPA|OnKure (OKUR) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) GDTC|Net earnings per share (EPS TTM) curis.com (CRIS)|Earnings per share for the last twelve months Tharimmune THAR|ADVB (Advanced Biomed Inc.) - Earnings per one share for the last 12 months|GNPX - Earnings per share for the last twelve months|CLDI: Earnings per share for the last twelve months|Sunshine Biopharma, Inc. (SBFM) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Xenetic Biosciences, Inc.|SLRX (Salarius Pharmaceuticals, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Purple Biotech Ltd (PPBT)|Net earnings per share (EPS TTM) AONC|Net earnings per share (EPS TTM) BeiGene Ltd (BGNE)|Earnings per share for the last twelve months Checkpoint Therapeutics CKPT|ELEV: Earnings per share for the last 12 months|iCAD Corp - Net earnings per share (EPS TTM)|Ikena Oncology, Inc. (IKNA) - Net earnings per share for the last 12 months|NTBL: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Viracta Therapeutics, Inc. (VIRX)|Earnings per share for the last twelve months MorphoSys AG|NAYA: Earnings per share for the trailing year|Net earnings per share for the last 12 months AAPGV (Ascentage Pharma)
